Filing Flows › Health Care › Tandem Diabetes Care (TNDM)
Tandem Diabetes Care (TNDM) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Tandem Diabetes Care (TNDM) Q3 2026 earnings results →
Q3 2026 Revenue up 14% year over year to $284M · 2¢ of every $1 of revenue lost · operating margin -0.8%
Tandem Diabetes Care made $284M in Q3 2026 (+14% Y/Y): Supplies and other $169M, Pump $115M. Operating margin -0.8%, net loss $7.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $283.7M in Q3 2026, up 14% year over year and up 11% from the previous quarter. Supplies and other was the largest line at 59% of revenue. Supplies and other added $29.6M year over year (up 21%), 86% of the total change.
Gross margin was 56.5%, up 2.7 points from Q3 2025. Operating costs exceeded revenue by $2.4M, an operating margin of -0.8%. Operating expenses grew 4% against revenue growth of 14%. The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $21.2M loss. Net interest and other expense of $5.3M was the main reason.
Operating cash flow was −$819K. Non-cash charges added back $4.5M of depreciation and amortization and $15.9M of share-based compensation. Working capital and other items used $14.1M. Capital expenditures of $4.7M exceeded it, leaving free cash flow of −$5.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $284M | +14% | -0.8% | −$7.1M | −$819K |
| Q2 2026 | 10-Q | Aug 6, 2026 | $255M | +6% | -5.4% | −$21.2M | −$34.6M |
| Q1 2026 | 10-Q | May 7, 2026 | $247M | +6% | -7.1% | −$20.4M | $11.1M |
| Q4 2025 | 10-K | Feb 19, 2026 | $290M | +3% | 2.9% | −$589K | $9.8M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $249M | +2% | -9.2% | −$21.2M | $8.3M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $241M | +8% | -21.5% | −$52.4M | −$9.5M |
| Q1 2025 | 10-Q | Apr 30, 2025 | $234M | +22% | -51.6% | −$131M | −$18.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Tandem Diabetes Care
References within this Annual Report to “Tandem,” “we,” “our,” “us,” “management,” or the “Company” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiaries. Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide. Our strategy is to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights. In support of this strategy, our Tandem pump platforms include t:slim X2 and Tandem Mobi (Mobi), both of which feature Control-IQ+ advanced hybrid closed-loop technology.
In its own words, from its 10-K, filed Feb 19, 2026.
Tandem Diabetes Care against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +14% against the peers' median +5%. Operating margin: -0.8% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Q3 2026 | $284M | +14% | -0.8% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Tandem Diabetes Care 10-Q on SEC EDGAR · CIK 1438133 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns TNDM and who is buying
More on TNDM
- How Tandem Diabetes Care makes money: revenue by segment
- Tandem Diabetes Care next earnings date and what analysts expect
- Tandem Diabetes Care stock forecast, price target and fair value
- Who owns Tandem Diabetes Care stock: holders, funds and Congress trades
- Tandem Diabetes Care guidance and outlook
- Is Tandem Diabetes Care a takeover target? LBO and rumors
- Tandem Diabetes Care recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Tandem Diabetes Care guidance history: guided vs reported
- Tandem Diabetes Care free cash flow by quarter
- Tandem Diabetes Care R&D spending by quarter
- Tandem Diabetes Care capital expenditures by quarter
- Tandem Diabetes Care Supplies and other revenue by quarter
- Tandem Diabetes Care Pump revenue by quarter